688321.SH
Shenzhen Chipscreen Biosciences Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 20.45
−4.97%Oct 29, 2026, 11:17 UTC
Microchip Biotech said its chairman, Xianping Lu, proposed that the company repurchase A-shares using its own and/or self-raised funds, with a total budget of RMB 30 million to RMB 50 million.
Source:Oct 16, 2026, 11:40 UTC
China’s National Medical Products Administration approved the clinical trial application for NW001 injection, developed by Shenzhen Chipscreen Biosciences and Chengdu Chipscreen New Domain Biotechnology, for treating advanced malignant tumors.
Source:Oct 14, 2026, 10:40 UTC
China's Center for Drug Evaluation accepted Microchip Biotech's clinical trial application for CS23546 tablets for combination treatment of relapsed or refractory lymphoma.
Source:Oct 12, 2026, 11:58 UTC
China’s National Medical Products Administration approved clinical trials of Chia Tai Tianqing’s CS43158 tablets for acute myeloid leukemia.
Source:Aug 19, 2026, 08:49 UTC
Chipscreen Biosciences reported its first-half 2026 results: net profit attributable to shareholders of 71.3806 million yuan, up 141.21% year-on-year.